OTCMKTS:PRTX - Protalex Stock Price, News, & Analysis

$0.0110
0.00 (0.00 %)
(As of 07/24/2019 04:43 AM ET)
Today's Range
$0.0110
Now: $0.0110
$0.0110
50-Day Range
$0.0110
MA: $0.03
$0.09
52-Week Range
$0.0002
Now: $0.0110
$0.5950
VolumeN/A
Average Volume9,774 shs
Market Capitalization$520,630.00
P/E RatioN/A
Dividend YieldN/A
Beta-1.39
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PRTX
Previous SymbolNASDAQ:PRTX
CUSIPN/A
Phone215-862-9720

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.04) per share

Profitability

Miscellaneous

Employees2
Market Cap$520,630.00
Next Earnings DateN/A
OptionableNot Optionable

Receive PRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTX and its competitors with MarketBeat's FREE daily newsletter.

Protalex (OTCMKTS:PRTX) Frequently Asked Questions

What is Protalex's stock symbol?

Protalex trades on the OTCMKTS under the ticker symbol "PRTX."

How were Protalex's earnings last quarter?

Protalex Inc. (OTCMKTS:PRTX) released its earnings results on Friday, April, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter. View Protalex's Earnings History.

Has Protalex been receiving favorable news coverage?

Media headlines about PRTX stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Protalex earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Protalex.

Who are some of Protalex's key competitors?

What other stocks do shareholders of Protalex own?

Who are Protalex's key executives?

Protalex's management team includes the folowing people:
  • Mr. Arnold P. Kling Esq., Pres & Director (Age 61)
  • Dr. William E. Gannon Jr., Chief Medical Officer & Member of Scientific Advisory Board
  • Dr. John Bruce Lundy McClain M.D., Medical Director & Member of Scientific Advisory Board
  • Dr. Michelle Catalina Ph.D., Director of Preclinical Studies & Member of Scientific Advisory Board

How do I buy shares of Protalex?

Shares of PRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalex's stock price today?

One share of PRTX stock can currently be purchased for approximately $0.0110.

How big of a company is Protalex?

Protalex has a market capitalization of $520,630.00. Protalex employs 2 workers across the globe.View Additional Information About Protalex.

What is Protalex's official website?

The official website for Protalex is http://www.protalex.com/.

How can I contact Protalex?

Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The company can be reached via phone at 215-862-9720 or via email at [email protected]


MarketBeat Community Rating for Protalex (OTCMKTS PRTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Protalex and other stocks. Vote "Outperform" if you believe PRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel